RecruitingPHASE2, PHASE3NCT06764238

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator: Xiaofan Zhu, MD
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Intervention: Blinatumomab (Group A)(drug)
Enrollment: 1800 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2031

Study locations (26)

Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
Anhui Provincial Children's Hospital, Hefei, Anhui, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Wuhan Children's Hospital, Wuhan, Hubei, China
Hunan Children's Hospital, Changsha, Hunan, China
Xiangya Hospital Central South University, Changsha, Hunan, China
Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China
Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China
+11 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06764238 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials